Acurx Pharmaceuticals Inc... (ACXP)
Acurx Pharmaceuticals Inc. (ACXP) Stock Price, Analysis & Data
| Bid | 1.14 |
| Market Cap | 6.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -7.5M |
| Beta | -2.03 |
| EPS (ttm) | -3.79 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.72 |
| P/B (ttm) | 0.74 |
| P/S (ttm) | n/a |
| Earnings Date | Aug 14, 2026 |
| Ask | 1.94 |
| Volume | 145,002 |
| Avg. Volume (20D) | 91,611 |
| Open | 1.54 |
| Previous Close | 1.47 |
| Day's Range | 1.50 - 1.61 |
| 52-Week Range | 1.33 - 8.34 |
| Analyst | Strong Buy |
| Price Target | 10 (553.59%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ACXP
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-pos...
Financial Performance
In 2025, Acurx Pharmaceuticals's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -7.97M, a decrease of -43.51%.
Financial StatementsAnalyst Forecast
According to 3 analyst ratings, the average rating for ACXP stock is "Strong Buy". The 12-month stock price forecast is 10, which is upside of 553.59% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
